fda approved glp-1 receptor agonists GI Adverse Effects of Glucagon-Like Peptide-1 GLP-1 Receptor Agonists: Small Molecule

SURPASS-CVOT compared once-weekly tirzepatide with dulaglutide in adults with type 2 diabetes and high cardiovascular risk, showing a 9% relative risk reduction in MACE (HR 0.92, 95% CI 0.83 to 1.01)

doi: 10.1016/j.endmts.2024.100168

Because doses are lower, patients dont experience the severe appetite suppression that can unintentionally lead to muscle loss

Multiple GLP-1 drugs linked to lower AFib risk GLP-1 receptor agonists (GLP-1-RAs) may be able to reduce a patient's risk of atrial fibrillation (AFib), according to new data presented at Heart Rhythm 2026 in Chicago

Interestingly, the same study found that, in rats, tirzepatide suppressed lipid intake without affecting sucrose (carbohydrate) consumption in a choice-based assay, implying that the effects of these medications may be macronutrient specific (Geisler et al., 2023)